AORT News and Press, Artivion Inc Com From 01/29/26

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results PR Newswire ATLANTA , Jan. 29, 2026 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announce...

2025-12-29 14:04:30 ET A lot of the value I see at Artivion ( AORT ) still lives in the clinic and is dependent upon clinical results, FDA approvals, and successful commercialization, but the company does continue to execute well, building confidence in the longer-term execution story.....

2025-12-22 12:12:50 ET More on healthcare stocks My S&P 500 Prediction On Sector Outperformers And Laggards In 2026 IHI: A Passive ETF For Medical Device Exposure XLV: The Simple Case For Overweighting U.S. Health Care Top 10 healthcare stocks according t...

2025-11-12 05:09:00 ET ... Read the full article on Seeking Alpha For further details see: Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update

2025-11-06 23:46:47 ET More on Artivion Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) Share Growth And Strong Clinical Results Continue To Support The Arti...

2025-11-06 23:46:09 ET Artivion, Inc. (AORT) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Pat MacKin Lance Berry - EVP, COO, CFO & Treasurer Conference Call Participants Lynn Lewis - Gilmartin Group LLC John McAulay ...

2025-11-06 16:51:25 ET More on Artivion Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) Share Growth And Strong Clinical Results Continue To Support The Artivion Story Seeking Alpha’s Quant Rating on Artiv...

Artivion Reports Third Quarter 2025 Financial Results PR Newswire Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant ...

Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial PR Newswire ATLANTA , Nov. 6, 2025 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT),  a leading cardiac and vascular surgery company focused on aortic disease, today announced the tre...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...